Jos Raats

Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom.

Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland.

ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

Staten Biotechnology BV develops drugs for the treatment of dyslipidemia. The company was founded by Paul da Silva Jardine, Daniel Rader and Alan Tall in 2014 and is headquartered in Nijmegen, the Netherlands.

Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan.

ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom.

Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts.

Van Lanschot Kempen NV (Broker) (Van Lanschot Kempen-Broker) is the broker-dealer division of Van Lanschot Kempen NV (AMS: VLK), a financial institution headquartered in Amsterdam, Netherlands. The firm was founded in 1903 and formerly known as Kempen & Co. NV. Van Lanschot Kempen-Broker provides securities broking to institutional investors, companies, financial institutions, (semi) public institutions, foundations and high net-worth individual clients.

Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom.

MeiraGTx Netherlands BV operates as a biopharmaceutical company developing local gene therapy for inflammatory diseases. It is into develop adeno-associated viral mediated gene therapy for patients with rheumatic conditions. The company was founded in 2005 and is headquartered in Amsterdam, the Netherlands.

Brabantse Ontwikkelings Maatschappij Holding BV (BOM) is an industrial and economic development agency headquarterd in Tilburg in the southern Netherlands. Established in 1983, BOM is funded and financed by the Dutch State and the Province of Noord-Brabant. The firm offers a range of services designed to create, develop, maintain and improve the industrial structure of the region through four core activities: venture capital, foreign investment, new business and industrial parks. In particular BOM manages the Technostartersfonds, also known as the TechnoStars funds, which are regional venture capital investment vehicles based in Eindhoven. The investors are primarily institutions and high-net worth private individuals.

Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021.

Axial Therapeutics, Inc. provides biopharmaceuticals. It is harnessing the link between the human get microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders. The company was founded by Sarkis Mazmanian and David H. Donabedian and is headquartered in Boston, MA.

Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.

TargEDys SA develops microbiome-based solutions for appetite regulation. It provides humanity with easy means of regulating their eating behaviors for the third millennium. The company was founded by Pierre Dechelotte and Gregory Lambert 2011 and is headquartered in Paris, France.

BioScience Managers Pty Ltd (Bioscience Managers) is a private equity & venture capital firm founded in 2003 by Jeremy Curnock Cook. The firm is headquartered in Melbourne, Australia.

Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.

Part of GSK Plc, Smithkline Beecham Holdings Corp. produces and distributes pharmaceutical products and dental healthcare products. The company is based in Wilmington, DE.

European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium.

The Alliance for Advanced Therapies’ mission is to improve the legislative, business and science climate for advanced therapies innovation in Europe. In order to do so, AAT promotes the interests of its members and the advanced therapies sector in Europe. AAT coordinates input to, and exchanges information with relevant European authorities. The Alliance also increases awareness of the sector among all relevant stakeholders, with a special focus on investors. Furthermore, AAT promotes increased funding for the sector from public and private sources.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

Part of TiGenix NV, Tigenix SAU is a Spanish company that collects all the research and development of health, agri-food and industrial products from its partners. The company is based in Tres Cantos, Spain. The company has been driving biotechnology in Spain since 1999 and have more than 300 associated companies, startups, and entities. The group Zendal, a 100%% Spanish biopharmaceutical group, includes seven companies focused on manufacturing and commercializing high-value biotechnology products. Tigenix SAU is a member of AseBio, and the membership fees vary depending on the type of entity and the company's age, annual turnover, and equity. The company offers discounts and economic advantages to their members. The AseBio Investor Day is an investment forum that aims to connect the Spanish biotechnology industry with investors.

Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France.

OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium.

Sutura Therapeutics Ltd. is a British biopharmaceutical company that is advancing biomolecular medicine through its Peptigo technology platform. The company is based in Macclesfield, UK. Sutura's team is made up of skilled and passionate professionals who bring a unique perspective to the table. The company was founded in 2020, and Edwin J. Wagena has been the CEO of the company since 2021.

Part of GSK Plc, Galvani Bioelectronics Ltd. is a pioneering research and British development company founded in 2016, dedicated to bringing bioelectronic therapies to patients. The company is based in Stevenage, UK. Galvani Bioelectronics combines GSK's therapeutics discovery and development knowledge with Verily's expertise in software and electronics for clinical applications. The company is developing therapies through implant-based direct modulation of specific neural signals to organs central in disease. These therapies are designed to be safe, precise in their therapeutic effect, and minimally invasive in their delivery through the use of small and efficient wireless electronics and keyhole surgery. Connected software will ensure that patients and physicians can effectively control and optimize the therapy.